Introduction
Myasthenia gravis (MG) is an autoimmune neurological disease mediated by immunoglobulin G autoantibodies to components of the postsynaptic neuromuscular junction (NMJ), characterized by fluctuating fatigable skeletal muscle weakness [1] . It represents a challenge for physicians due to the diversity of disease manifestations and possibility of respiratory complications. Worsening of myasthenic symptoms often requires hospitalization of the patients and plasma exchange therapy and IGiv may represent a choice in the acute management of this neuromuscular junction disease. We report the case of 45-year-old female patient with myasthenia gravis who developed laboratory signs of pancreatitis during the IGiv therapy.
Case Report
A 45-year-old woman with an history of myasthenia gravis, arrived at the emergency department with symptoms of dysphagia for liquids and solids, from [2] . This type of elimination is, by definition, capacity-limited (saturable), and represents a significant contributor to the kinetics of antibodies distribution and elimination [2] .
Another possible determinant in the catabolism of IGiV may be represented by the lymphatic system capability to remove the macromolecules from the extracellular tissue's compartment [3] . In our patient an iatrogenic abdominal bleeding was mandatory for vascular surgery of left Gerota's fascia veins, that if damaged, may induce a condition of lymphatic congestion, with a possible accumulation of cellular catabolism products and the activation of various lymphatic/endothelial immune mediating signaling pathways [4] . Thus, it is possible that, in our case, the high dosage therapeutic IGiv regimen, together with an altered kinetics of the receptor mediated -endocytosis, and a local lymphatic vessels congestion may lead the pancreatic damage, through several mechanisms, including inducible nitric oxide synthaseexpressing, and decreased migration of the macrophages within the lymphatics [5] . Subsequently, B cells in the draining lymph nodes, may translocate from the follicles to the paracortical sinuses, via a yet to be determined mechanism, clogging the afferent lymphatics and triggering pancreatic damage. Interestingly, that alterations of receptor-mediated endocytosis and of lymphatic flow have been identified in several autoimmune diseases such as, chronic autoimmune pancreatitis [6] , rheumatoid arthritis [7] , while, specific IgG4 antibodies have been strongly implicated in mediating diseases such as pemphigus foliaceus [8] and some cases of membranous glomerulonephritis [8] .
In conclusion, our patient shows characteristics which have never been reported. An accumulation of similar cases may prompt us to better understand the safety's profile of IGiv therapy in neurological autoimmune diseases. two months. She also reported complaints of dysphonia from two weeks. Both symptoms worsened during the day. Physical examination on admission revealed complete eye movements without diplopia in the tests of fatigue, symmetric facial movements, tongue protrusion in the midline and symmetrical vocal folds, with no lesions, while, a difficult in the elevation of the soft palate, and a slight palpebral ptosis, in the left eye were found. Remaining neurological examination also revealed a slight weakness of the proximal limbs muscles. Standard hematological tests and blood chemistries (complete blood count differential, platelet count, electrolytes, serum creatinine, liver and pancreatic enzymes, uric acid, thyroid function, cyanocobalamin and folic acid plasma levels) were normal. A nasogastric tube was placed to prevent pneumonia inhalation and, a femoral vein cannulation was required, in order to perform a plasma exchange therapy.
An iatrogenic left femoral artery injury due to the central venous catheter placement did not permit to perform the plasma exchange therapy and, the patient underwent vascular cover stenting. Subsequently, CT-scan of abdomen was performed and the presence of an active bleeding, was mandatory for a surgical hemostasis of the left iliac artery and of the Gerota's fascia veins. In the following days, the patient was moved to the intensive-care unit and a IGiv treatment (Venital, 2.4 g/kg, administered over six days) plus steroid therapy (IV dexamethasone, gradually increased at the dose of 14 mg daily) and oral pyridostigmine (60 mg 4-times a day) has been initiated, with a partial improvement of the proximal limbs weakness. Before the IGiv therapy initiation, serum immunoglobulin levels were within the normal values. In particular total IgG-antibodies were 1050 mg/dL (normal value of our laboratory 695-1750 mg/dL). Seven days after, the patients was admitted to our neurological department to continue medical treatment. An additional IGiv immunomodulatory therapy was begun (Venital, 2.0 g/kg, administered over five days), maintaining steroid treatment and oral pyridostigmine. The IGiv therapy was discontinued three days after, due to an increase of the pancreatic enzymes, greater than six times the upper limit of normal values, together with slight increase of total serum IgG-antibodies levels, above the normal ranges of our laboratory (1955 mg/dL).
This laboratory abnormalities resolved, without treatment, five day after the discontinuation of IGiv. One month later, the patient underwent a new high-dosage IGiv therapy cycle (Venital, 2.0 g/kg, administered over five days), because the worsening of dysphagic symptoms: again, the pancreatic enzymes raised more than five times the upper limit of normal values and, then, decreased few days after the discontinuation of the IGiv. Clinical examination was negative, while an abdominal magnetic resonance with cholangiography evidenced a slight hyper-intensity of the pancreatic head. Once Again, an increase of total serum IgG-antibodies levels, above the normal ranges of our laboratory (1857 mg/dL) was found in our patient.
Discussion
Our patient had an increase of pancreatic enzyme plasma
